APLM
$19.50
Market ClosedAs of Mar 17, 8:00 PM UTC
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
Intraday
Custom Range:to
No data available for this range. Intraday data may be limited by the exchange.
Recent News
No recent news found.